7–5 months, and it could predict a better survival in unresctable HCC patients treated with sorafenib combined with click here TACE. Key Word(s): 1. sorafenib; 2. adverse events; 3. overall survival; 4. HCC; Presenting Author: LEI LIU Additional Authors: YAN ZHAO, HUI CHEN, XINGSHUN QI, YONGZHAN NIE, GUOHONG HAN, KAICHUN WU, DAIMING FAN Corresponding Author: GUOHONG HAN Affiliations: Xijing Hospital of Digestive Diseases Objective: The transjugular intrahepatic portosystemic shunt (TIPS) represents a major advance in the treatment
of complications of portal hypertension. However, this procedure is contraindicated in hepatocellular carcinoma (HCC) patients with portal vein thrombosis (PVTT). This study was done to evaluate the effect of TIPS in those patients with portal hypertension and determine the predictors of survival after TIPS creation. Methods: Between 2005 and 2011, 58 consecutive HCC patients
with PVTT were enrolled in this study due to their portal hypertension. All the patients underwent TIPS placement to treat the portal hypertension. Effective shunt creation was assessed by the decrease of the portal pressure gradient (less than 12 mmHg) or if good patency and flow were seen on a Doppler examination. Complications and patient survival were evaluated after TIPS. Results: After TIPS, none the 58 patients experienced major complications such as hemorrhage or contrast extravasation, spontaneous bacterial peritonitis. Portosystemic pressure gradient was decreased BAY 73-4506 manufacturer by 14 mmHg (51.5%) on average. Severe diarrhea was controlled successfully in all 9 patients (100%). During the follow-up period (range 11.0–1713 days;
mean 78.5 days), 56 patients died and two remained alive. The median survival period after TIPS was 77 days. Multivariate Cox regression analysis showed that ascites (p = 0.026), white blood cell (p = 0.007) and degree of thrombosis (p < 0.001) were independent prognostic factors for patient survival. Conclusion: TIPS may be safe and effective for the palliative treatment of portal hypertension in HCC patients with PVTT. Ascites, white blood cell and degree Carnitine palmitoyltransferase II of thrombosis were poor prognostic factors for determining the patient survival period after TIPS. Key Word(s): 1. TIPS; 2. HCC; 3. PVTT; 4. portal hypertension; Presenting Author: MEI-HSUAN LEE Additional Authors: HWAI-I YANG, YU-JU LIN, CHIN-LAN JEN, SHENG-NAN LU, YONG YUAN, GILBERT L’ITALIEN, CHIEN-JEN CHEN Corresponding Author: MEI-HSUAN LEE Affiliations: National Yang-Ming University; Genomics Research Center; Department of Gastroenterology; Global Health Economics and Outcome Research; Bristol-Myers Squibb Company Objective: The single nucleotide polymorphisms (SNP) near IL28B (rs8099917 and rs12979860) have been documented to be associated with antiviral response or spontaneous HCV clearance in chronic hepatitis C patients in previous genome-wide association studies.